Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Barry A. Singer"'
Autor:
Barry A. Singer, Sibyl Wray, Mark Gudesblatt, Barbara Bumstead, Tjalf Ziemssen, Ashley Bonnell, Matthew Scaramozza, Seth Levin, Mathura Shanmugasundaram, Hailu Chen, Jason P. Mendoza, James B. Lewin, Sai L. Shankar
Publikováno v:
Neurology and Therapy, Vol 13, Iss 4, Pp 1273-1285 (2024)
Abstract Introduction In EVOLVE-MS-1 (NCT02634307), mean absolute lymphocyte count (ALC) on diroximel fumarate (DRF) declined from baseline by approximately 28% in year 1, then stabilized, similar to ALC decline observed with dimethyl fumarate (DMF).
Externí odkaz:
https://doaj.org/article/8438206336ce48d6a191208930b85bc7
Autor:
Alasdair J. Coles, Anat Achiron, Anthony Traboulsee, Barry A. Singer, Carlo Pozzilli, Celia Oreja-Guevara, Gavin Giovannoni, Giancarlo Comi, Mark S. Freedman, Tjalf Ziemssen, Debora Shiota, Andreea M. Rawlings, Alana T. Wong, Magdalena Chirieac, Xavier Montalban
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 16 (2023)
Background and objectives: Alemtuzumab demonstrated superior efficacy versus subcutaneous interferon (IFN) beta-1a in participants with relapsing-remitting multiple sclerosis in the 2-year CARE-MS I and II trials. Efficacy was maintained in the 4-yea
Externí odkaz:
https://doaj.org/article/d1ccbb1ea3314b49a9e39f7237862350
Autor:
Antonio Bertolotto, Rafael Arroyo, Elisabeth G. Celius, Giancarlo Comi, Eva Kubala Havrdova, William David Honeycutt, Samuel F. Hunter, Guillermo Izquierdo, Barbara Kornek, Tamara Miller, Dimos D. Mitsikostas, Barry A. Singer, Tjalf Ziemssen, Luke Chung, Nadia Daizadeh, Salman Afsar, Lobat Hashemi, Peter Senior
Publikováno v:
Neurology and Therapy, Vol 9, Iss 2, Pp 443-457 (2020)
Plain Language Summary This study looked at alemtuzumab, an approved treatment for multiple sclerosis (MS). People who receive alemtuzumab may develop thyroid problems. The researchers wanted to know whether people who developed thyroid problems with
Externí odkaz:
https://doaj.org/article/3bcc37fc46e84de69be4eb2c49df7148
Autor:
Annette Wundes, Sibyl Wray, Ralf Gold, Barry A. Singer, Elzbieta Jasinska, Tjalf Ziemssen, Jerome de Seze, Pavle Repovic, Hailu Chen, Jerome Hanna, Jordan Messer, Catherine Miller, Robert T. Naismith
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Background: Diroximel fumarate (DRF) is a novel oral fumarate approved for relapsing forms of multiple sclerosis (MS). DRF demonstrated significantly improved gastrointestinal (GI) tolerability versus dimethyl fumarate (DMF) with fewer days of Indivi
Externí odkaz:
https://doaj.org/article/7dcf8de81cf441938990675a654ee297
Autor:
Barry A. Singer
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 10 (2017)
Natalizumab, a monoclonal antibody that blocks lymphocyte infiltration in the central nervous system, is a valuable tool in the treatment of relapsing forms of multiple sclerosis (MS). In a phase III clinical trial comparing natalizumab with placebo
Externí odkaz:
https://doaj.org/article/da58f4931c824564b46f3650909d6d1b
Autor:
Barry A. Singer
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 6 (2013)
Fingolimod, the first oral disease-modifying therapy (DMT) approved for the treatment of multiple sclerosis (MS) and the only sphingosine 1-phosphate receptor modulator approved for any disease state, represents an important addition to the expanding
Externí odkaz:
https://doaj.org/article/823fc51b2e4f4bb2919801cfb110de60
Autor:
Sibyl Wray, Florian Then Bergh, Annette Wundes, Douglas L. Arnold, Jelena Drulovic, Elzbieta Jasinska, James D. Bowen, Donald Negroski, Robert T. Naismith, Samuel F. Hunter, Mark Gudesblatt, Hailu Chen, Jennifer Lyons, Sai L. Shankar, Shivani Kapadia, Jason P. Mendoza, Barry A. Singer
Publikováno v:
Advances in Therapy. 39:1810-1831
Publikováno v:
Multiple Sclerosis Journal. 28:1219-1228
Background: No evidence of disease activity (NEDA-3) is a patient-centric outcome increasingly used as the goal of multiple sclerosis treatment. Objective: Determine treatment durability of cladribine tablets beyond 2 years considering the variable b
Autor:
Luke Chung, Samuel F. Hunter, Barry A Singer, Antonio Bertolotto, Guillermo Izquierdo, Lobat Hashemi, Tjalf Ziemssen, Nadia Daizadeh, William David Honeycutt, Elisabeth Gulowsen Celius, Dimos-Dimitrios Mitsikostas, Salman Afsar, Barbara Kornek, Tamara Miller, Peter A. Senior, Rafael Arroyo, Giancarlo Comi, Eva Havrdova
Publikováno v:
Neurology and Therapy, Vol 9, Iss 2, Pp 443-457 (2020)
Neurology and Therapy
Neurology and Therapy
Introduction In clinical trials of alemtuzumab, autoimmune thyroid adverse events (AEs) were frequent. Here, we assess the impact of thyroid AEs on health-related quality of life (HRQL) in alemtuzumab-treated patients with relapsing-remitting multipl
Autor:
Mark S. Freedman, Barry A Singer, Patrick Vermersch, Aaron Boster, Heinz Wiendl, Guillermo Izquierdo, Luke Chung, Oscar Fernandez, David Margolin, Tjalf Ziemssen, Bart Van Wijmeersch, Sibyl Wray, Simon Broadley, K. Thangavelu, Jan Lycke, Basil Sharrack, Brian Steingo, Carlo Pozzilli
Publikováno v:
Article
Multiple Sclerosis (Houndmills, Basingstoke, England)
Multiple Sclerosis (Houndmills, Basingstoke, England)
Background:Alemtuzumab is administered as two annual courses for relapsing-remitting multiple sclerosis (MS). Patients may relapse before completing the two-course regimen. Objective: The objective was to evaluate 6-year outcomes in patients who rela